Our recent study with a rat model of ischemic stroke showed that occludin degradation occurred in the early phase of ischemic stroke and contributed to BBB disruption (Pan et al., 2017), suggesting that occludin might be a potential biomarker for predicting the risk of HT. The gene discussed is OCLN; the disease is hematocrit.